Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun 7:10:1100006.
doi: 10.3389/fcvm.2023.1100006. eCollection 2023.

Efficacy and safety of Danlou tablets in traditional Chinese medicine for coronary heart disease: a systematic review and meta-analysis

WeiLi Mao #  1 , Peng Lu #  2 , Renhong Wan  3 , Kaili Mao  1 , Yanzhu Lv  3 , Jie Hu  1 , Zhenling Fu  1 , Jun Wang  1
Affiliations
Review

Efficacy and safety of Danlou tablets in traditional Chinese medicine for coronary heart disease: a systematic review and meta-analysis

WeiLi Mao et al. Front Cardiovasc Med. .

Abstract

Background: Danlou tablets exert auxiliary advantages in treating coronary heart disease (CHD), but a summary of evidence-based proof is lacking. This study aims to systematically evaluate Danlou tablets in treating CHD from two aspects, including efficacy and safety.

Methods: By a thorough retrieval of the four English databases, namely, PubMed, The Cochrane Library, Embase, and Web of Science, and the four Chinese databases, namely, CNKI, Wanfang, VIP database, and China Biomedical Literature Service System, we found all randomized controlled trials (RCTs) related to Danlou tablets in treating CHD. The retrieval time was from the construction of the database to April 2022. We engaged two researchers to screen the studies, extract the required data, and assess the risk of bias. We then used RevMan5.3 and STATA.14 software to conduct a meta-analysis. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) was used to evaluate the quality of outcome indicators.

Results: Seventeen RCTs involving 1,588 patients were included. The meta-analysis results are displayed as follows: clinical treatment effect [risk ratio (RR) = 1.22, 95% confidence interval (CI): 1.16, 1.28, P < 0.00001], angina pectoris duration [MD = -0.2.15, 95% CI: -2.91, -1.04, P < 0.00001], angina pectoris frequency [standard mean difference (SMD) = -2.48, 95% CI: -3.42, -1.54, P < 0.00001], angina pectoris degree [SMD = -0.96, 95% CI: -1.39, -0.53, P < 0.0001], TC [MD = -0.71, 95% CI: -0.92, -0.51, P < 0.00001], TG [MD = -0.38, 95% CI: -0.53, -0.22, P < 0.00001], low-density lipoprotein cholesterol [MD = -0.64, 95% CI: -0.76, -0.51, P < 0.00001], high-density lipoprotein cholesterol [MD = 0.16, 95% CI: 0.11, 0.21, P < 0.00001], and adverse events [RR = 0.46, 95% CI: 0.24, 0.88, P = 0.02].

Conclusion: The current evidence suggests that the combination of Danlou tablets and Western medicine can enhance the efficacy of CHD and does not increase adverse events. However, because of the limited number and quality of the included studies, the results of our study should be treated with caution. Further large-scale RCTs are necessary to verify the benefits of this approach.

Keywords: Danlou tablet; complementary alternative therapy; coronary heart disease; meta-analysis; randomized controlled trial.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer Lin Li declared a shared affiliation with the authors RW and YL to the handling editor at the time of review.

Figures

Figure 1
Figure 1
Flow diagram.
Figure 2
Figure 2
Sensitivity analysis of the effectiveness of clinical treatment.
Figure 3
Figure 3
Sensitivity analysis of the frequency of angina pectoris.
Figure 4
Figure 4
Sensitivity analysis of the duration of angina pectoris.
Figure 5
Figure 5
Sensitivity analysis of the degree of angina pectoris.
Figure 6
Figure 6
Sensitivity analysis of TC.
Figure 7
Figure 7
Sensitivity analysis of TG.
Figure 8
Figure 8
Sensitivity analysis of LDL-C.
Figure 9
Figure 9
Sensitivity analysis of HDL-C.
Figure 10
Figure 10
Sensitivity analysis of adverse events.
Figure 11
Figure 11
Funnel plot of clinical treatment effects.
See this image and copyright information in PMC

References

    1. Timmis A, Townsend N, Gale C, Grobbee R, Maniadakis N, Flather M, et al. European Society of Cardiology: cardiovascular disease statistics 2017. Eur Heart J. (2018) 39(7):508–79. 10.1093/eurheartj/ehx628 - DOI - PubMed
    1. Yu YF, Zhou ML, Luo XX, Zhao YC, Zhou XH, Zhang YF, et al. Meta analysis and trial sequential analysis of colchicine in the treatment of coronary heart disease. Chin Circ J. (2021) 36(7):659–66. CNKI:SUN:ZGXH.0.2021-07-006
    1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. (2006) 3(11):e442. 10.1371/journal.pmed.0030442 - DOI - PMC - PubMed
    1. Liu GP, Li GZ, Wang YL, Wang YQ. Modelling of inquiry diagnosis for coronary heart disease in traditional Chinese medicine by using multi-label learning. BMC Complement Altern Med. (2010) 10(13):37. 10.1186/1472-6882-10-37 - DOI - PMC - PubMed
    1. Liu Q, Dong T, Xi M, Gou L, Bai Y, Hou L, et al. Tongxinluo capsule combined with atorvastatin for coronary heart disease: a systematic review and meta-analysis. Evid Based Complement Alternat Med. (2021) 2021:9413704. 10.1155/2021/9413704 - DOI - PMC - PubMed